Displaying drugs 8826 - 8850 of 9175 in total
CV-MG01
Investigational
AT-GTX-502
AT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.
Investigational
BMN-045
Experimental
Withdrawn
AMZ002
AMZ002 is a sterile injectable hormone developed as a purified synthetic polypeptide alternative to current FDA-approved epileptic seizure treatments.
Investigational
IMCY-0141
IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves.
Investigational
LY3884961
LY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.
Investigational
AVI-014
AVI-014 is a glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF).
Investigational
Autologous Human Peripheral Blood Lymphocytes
Investigational
P140K methylguanine-DNA-methyltransferase mutant CD34+ cells
Investigational
Virulizin
Investigational
SRX-1177
Investigational
Spanlecortemlocel
Investigational
ATG-101
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Activated natural killer cell therapy
Investigational
Adenovirus/PNP
Investigational
ETBX-041
Investigational
Carlecortemcel-L
Investigational
PBCAR269A
Investigational
PBCAR20A
Investigational
P-2045 Re-188
Investigational
ALM201
ALM201 is an anti-angiogenic synthetic peptide identified from the endogenous human protein, FKBPL. It is being investigated in the treatment of various cancers.
Investigational
KAb201
Investigational
Etevritamab
Investigational
hu3S193
Investigational
Displaying drugs 8826 - 8850 of 9175 in total